Non-Interventional Study (NIS) Protocol Amendment

Amendment Number	3
NIS Name/Code	NIS-ORU-IRE-2009/1
Date	25 April 2012
NIS Protocol dated	8 December 2009
NIS Protocol Addendum dated	8 December 2009

Epidemiological study to describe NSCLC clinical management patterns in Central Eastern Europe and Russia. Lung-EPICLIN

Sponsor:

AstraZeneca
Begovaya Street, 3, bld. 1
125289 Moscow, Russia
Tel:+74957995699
Fax: +74957995698

Protocol Amendmend #3 is issued to change text of Protocol Addendum, version 2 dated 08.12.2009.

This amendment affects all sites participating in the study.

Section of Protocol Addendum amended:

6 STATISTICAL AND ANALYTICAL METHODS

6.2 Determination of sample size

Previous text:

The primary objective of this sub-study is to evaluate the distribution of EGFR mutation status (M+, M-, Mx) in the Russian population. The sample size calculation was based on estimates of EGFR mutation rates with a 95% confidence interval of no more that +/- 5% around the point estimates. For the descriptive analysis, 300 tissue samples from NSCLC patients will allow to estimate an expected EGFR mutation-positive proportion of 0.15 with a precision of 0.044, which means estimating 15% with a confidence interval from 10.6% to 19.4% (α=0.05). Taking into account probable drop-out due to non-appropriate for EGFR analysis tissue samples, 500 patients enrolled will provide enough population for EGFR analysis

Revised text:

The primary objective of this sub-study is to evaluate the distribution of EGFR mutation status (M+, M-, Mx) **with identification of EGFR mutation type (EGFR del746-750 and EGFR Leu858Arg)** in the Russian population. The sample size calculation was based on estimates of EGFR mutation rates with a 95% confidence interval of no more that +/- 5% around the point estimates. For the descriptive analysis, 300 tissue samples from NSCLC patients will allow to estimate an expected EGFR mutation-positive proportion of 0.15 with a precision of 0.044, which means estimating 15% with a confidence interval from 10.6% to 19.4% (α=0.05). Taking into account probable drop-out due to non-appropriate for EGFR analysis tissue samples, 500 patients enrolled will provide enough population for EGFR analysis. **Information about types of EGFR gene mutations will be reported in final statistical analysis data**.

Reason for Amendment:

Reason for Amendment is data obtained on frequency of EGFR mutation types in Russian population. Amendment is agreed with National Coordinators and Study Sponsor.

Person who initiated the Amendment:

Vera Karaseva, Head of Medical Advisers Group.

AstraZeneca

Non-Interventional Study (NIS) Protocol Amendment #3 – Appendix A

NIS Name/Code: NIS-ORU-IRE-2009/1

Amendment Number: 3

Date: 25 April 2012

NIS Protocol dated: 8 December 2009

NIS Protocol Addendum dated: 8 December 2009

Appendix A
Signatures

AstraZeneca

ASTRAZENECA SIGNATURE(S)

Epidemiological study to describe NSCLC clinical management patterns in Central Eastern Europe and Russia. EPICLIN-LUNG

I agree to the terms of this Protocol Amendment #3, dated 25 April 2012.

AstraZeneca Marketing Company representative

Professor Stepanov Alexey
Medical Director
AstraZeneca Russia
Begovaya St., 3, bld 1
125284, Moscow Russia

Tel: +74957995699

Date
(Day Month Year)

SIGNATURE OF NATIONAL COORDINATORS

Epidemiological study to describe NSCLC clinical management patterns in Central Eastern Europe and Russia. EPICLIN-LUNG

I agree to the terms of this Protocol Amendment #3, dated 25 April 2012.

Signature

Professor Tyulandin Sergey Russian Cancer Research Center Department of Clinical Pharmacology and Chemotherapy Kashirskoye Sosse, 23, 115487, Moscow, Russia Tel: + 74953249844	Date (Day Month Year)

SIGNATURE OF NATIONAL COORDINATORS

Epidemiological study to describe NSCLC clinical management patterns in Central Eastern Europe and Russia. EPICLIN-LUNG

I agree to the terms of this Protocol Amendment #3, dated 25 April 2012.

Signature

Professor Imyanitov Evgeny
Cancer Research Institute
Department of Cancer Growth Biology
Leningradskaya St., 68
197758 S-Petersburg Russia,
Tel: + 78125968951

Date
(Day Month Year)

SIGNATURE OF NATIONAL COORDINATORS

Epidemiological study to describe NSCLC clinical management patterns in Central Eastern Europe and Russia. EPICLIN-LUNG

I agree to the terms of this Protocol Amendment #3, dated 25 April 2012.

Signature

Professor Moiseenko Vladimir Cancer Research Institute Department of Biotherapy Leningradskaya St., 68 197758 S-Petersburg Russia, Tel: + 78125968822	Date (Day Month Year)